What are the appropriate vaccine recommendations for a patient who has recently recovered from an acute shingles episode, including timing and choice of recombinant zoster vaccine (Shingrix) and other routine adult immunizations such as influenza, COVID‑19 booster, tetanus‑diphtheria‑pertussis (Tdap) and pneumococcal vaccines?

Vaccine Recommendations After Acute Shingles

Administer the recombinant zoster vaccine (Shingrix) starting at least 1 year after the acute shingles episode has resolved, and proceed with all other routine adult immunizations (influenza, COVID-19, Tdap, pneumococcal) without delay—these can be given immediately and do not require waiting.

Recombinant Zoster Vaccine (Shingrix) Timing

The most critical decision involves timing of Shingrix after acute herpes zoster. The 2024 NCCN guidelines recommend administering recombinant zoster vaccine (RZV) to adults aged ≥50 years, given in 2 doses 2-6 months apart 1. While the guidelines state vaccination is recommended "regardless of prior episode of herpes zoster," they do not specify exact timing post-acute infection.

Research evidence provides practical guidance: A prospective study demonstrated that zoster vaccine administered either 6-12 months or 1-5 years after acute shingles produces similar immunogenicity, with significant increases in both VZV IgG and T-cell responses in both timing groups 2. This suggests waiting at least 6-12 months is reasonable, though waiting up to 1 year is a conservative approach that ensures complete resolution and allows natural immunity to stabilize.

Shingrix Dosing Schedule

• Two doses separated by 2-6 months (standard schedule) 1
• For high-risk patients ≥18 years, doses can be given 1-2 months apart if a shorter schedule is beneficial 1
• If patient previously received live zoster vaccine (Zostavax), give RZV at least 2 months after the last Zostavax dose 1

Routine Adult Immunizations: Proceed Immediately

All other adult vaccines should be administered according to standard schedules without waiting:

Influenza Vaccine

• Administer annually with trivalent inactivated influenza vaccine (IIV) 3
• Can be co-administered with Shingrix safely 4, 5

COVID-19 Booster

• Give updated 2024-2025 vaccine formulation as recommended for the patient's age and risk category 3
• Co-administration with Shingrix is safe and does not alter immunogenicity 4

Tetanus-Diphtheria-Pertussis (Tdap)

• Administer Tdap if not received within the past 10 years 1, 3
• Co-administration with Shingrix shows similar reactogenicity and immunogenicity profiles 6, 4
• Common side effects when co-administered include injection site pain (45%), myalgia (44%), and fatigue (32%) 6

Pneumococcal Vaccines

• For pneumococcal vaccine-naïve patients: Give PCV20 (preferred) as a single dose 1
• Alternative: PCV15 followed by PPSV23 at least 8 weeks later 1
• Co-administration with Shingrix is safe, though shivering (16% vs 7%) and fever (21% vs 7%) are more common with co-administration of RZV and PPSV23 compared to sequential administration 4

Co-Administration Strategy

Multiple vaccines can be safely co-administered with Shingrix. A comprehensive review of five phase III trials involving 3,974 participants demonstrated that co-administration of RZV with IIV4, PPSV23, Tdap, PCV13, and COVID-19 mRNA vaccines resulted in:

• Non-inferior immune responses for both RZV and co-administered vaccines 4
• Similar overall adverse event profiles 4
• Myalgia as the most common systemic reaction (38-64% with co-administration) 4

Practical Co-Administration Approach

1. Prioritize influenza and COVID-19 vaccines immediately if patient is due or overdue
2. Add pneumococcal vaccine if indicated based on age and vaccination history
3. Include Tdap if due (every 10 years)
4. Schedule Shingrix separately at 1 year post-shingles, or consider co-administering with routine vaccines if patient is ≥1 year post-acute episode

Important Caveats

Contraindications to Shingrix

• Severe allergic reaction to any component 7
• Pregnancy (though no specific harm documented, delay until postpartum) 7

Monitoring Considerations

• Guillain-Barré syndrome (GBS): Postmarketing data identified approximately 3 excess GBS cases per million doses (6 per million after first dose) 7. While causality is not definitively established, clinicians should be aware of this potential association
• Patients may experience decreased arm mobility lasting >1 week 7
• Reactogenicity is higher with Shingrix than other adult vaccines, but most reactions are mild-to-moderate and transient 8

Special Populations

• Immunocompromised patients ≥18 years: RZV is recommended and not contraindicated (unlike live zoster vaccine) 1, 8
• Adults 50-59 years: Despite ACIP recommendations, only 29% of primary care providers are fully aware of recommendations for this age group 9, leading to lower uptake

Algorithm Summary

For a patient recently recovered from acute shingles:

1. Immediate (now):

   • Influenza vaccine (annual)
   • COVID-19 booster (per current recommendations)
   • Tdap (if ≥10 years since last dose)
   • Pneumococcal vaccine (if indicated by age/history)

2. At 1 year post-shingles:

   • Shingrix dose #1
   • Can co-administer with any routine vaccines due at that time

3. 2-6 months after Shingrix dose #1:

   • Shingrix dose #2

This approach maximizes protection against vaccine-preventable diseases while respecting the natural immune response to acute herpes zoster and optimizing Shingrix immunogenicity.